ID   A549/TR
AC   CVCL_C5S0
DR   ChEMBL-Cells; CHEMBL4483127
DR   ChEMBL-Targets; CHEMBL4483226
DR   Wikidata; Q116048464
RX   PubMed=26498137;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0023 ! A-549
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 29-06-23; Version: 3
//
RX   PubMed=26498137; DOI=10.3892/ijo.2015.3216;
RA   Kim K.-C., Baek S.-H., Lee C.;
RT   "Curcumin-induced downregulation of Axl receptor tyrosine kinase
RT   inhibits cell proliferation and circumvents chemoresistance in
RT   non-small lung cancer cells.";
RL   Int. J. Oncol. 47:2296-2303(2015).
//